Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.
It has long been recognized that individuals with ovarian cancer who initially respond to a platinum-containing chemotherapeutic regimen may exhibt a second response to platinum (cisplatin or carboplatin) at the time of recurrence. In this report, we describe three individuals with metastatic endometrial cancer who demonstrated secondary responses to platinum/paclitaxel-based regimens. Endometrial cancer should be added to the list of malignancies for which platinum and/or paclitaxel are considered as second-line treatment options in patients previously responding to the agents.
Markman
M
M
Cleveland Clinic Taussig Cancer Center and the Department of Gynecology/Obstetrics and Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. markmam@cesmtp.ccf.org
Kennedy
A
A
Webster
K
K
Kulp
B
B
Peterson
G
G
Belinson
J
J
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D010984:Platinum / Q000627:therapeutic use*; D012074:Remission Induction
D010984:Platinum; D017239:Paclitaxel